Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation - PubMed (original) (raw)
Comparative Study
Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation
M J Schell et al. J Clin Oncol. 1989 Jun.
Abstract
One hundred seventy-seven children and young adults with various malignant neoplasms were prospectively tested for hearing loss after they had received cisplatin (n = 146), cranial irradiation (n = 18), or both (n = 13). Adequate renal function, no history of treatment with ototoxic drugs other than cisplatin, and availability for repeated audiometric testing were requirements for enrollment. Substantial hearing loss, defined as a hearing threshold of 50 dB or greater, was noted in only 11% of the cohort on tests conducted at the common speech frequencies (500 to 3,000 Hz). About half the patients had substantial deficits at higher frequencies (4,000 to 8,000 Hz). The probability of substantial hearing loss was directly related to the cumulative dose of cisplatin. In nonirradiated patients tested at the speech frequencies, there was a negligible risk of substantial deficits over the dose range of 90 to 360 mg/m2. As the dose increased to 720 mg/m2, the risk increased to 22%. In irradiated patients who later received cisplatin, cumulative drug doses as low as 270 mg/m2 were associated with a high probability of substantial hearing loss, suggesting potentiation of ototoxicity when these therapies are used together. Hearing acuity was either not affected or only minimally decreased in the irradiation-only group. Younger age, prior irradiation, and the presence of a CNS tumor each contributed significantly to the severity of hearing deficits at given cisplatin dose levels. We conclude that early increases in hearing threshold at a stimulus frequency of 4,000 Hz indicate probable subsequent deficits at lower frequencies, especially in young children with CNS tumors who have received cranial irradiation. The probability charts derived from this analysis should provide a useful tool for predicting hearing loss in the speech frequencies.
Comment in
- Treatment-related ototoxicity.
Walker DA, Waters KD. Walker DA, et al. J Clin Oncol. 1990 Jan;8(1):179-80. doi: 10.1200/JCO.1990.8.1.179. J Clin Oncol. 1990. PMID: 2295908 No abstract available.
Similar articles
- Ototoxicity of preradiation cisplatin for children with central nervous system tumors.
Kretschmar CS, Warren MP, Lavally BL, Dyer S, Tarbell NJ. Kretschmar CS, et al. J Clin Oncol. 1990 Jul;8(7):1191-8. doi: 10.1200/JCO.1990.8.7.1191. J Clin Oncol. 1990. PMID: 2358836 - [Detection of late ototoxic side effect of cisplatin by distortion otoacoustic emission (DPOAE)].
Biró K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I. Biró K, et al. Magy Onkol. 2006;50(4):329-35. Epub 2007 Jan 10. Magy Onkol. 2006. PMID: 17216007 Hungarian. - Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, Bodrogi I. Biro K, et al. Oncology. 2006;70(3):177-84. doi: 10.1159/000093776. Epub 2006 Jun 2. Oncology. 2006. PMID: 16757924 - Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ, Kraus DH, Budnick AS, Bayer LA, Finlay JL. Freilich RJ, et al. Med Pediatr Oncol. 1996 Feb;26(2):95-100. doi: 10.1002/(SICI)1096-911X(199602)26:2<95::AID-MPO5>3.0.CO;2-P. Med Pediatr Oncol. 1996. PMID: 8531860 - Ototoxicity monitoring in children treated with platinum chemotherapy.
Brooks B, Knight K. Brooks B, et al. Int J Audiol. 2018 Sep;57(sup4):S34-S40. doi: 10.1080/14992027.2017.1355570. Epub 2017 Jul 24. Int J Audiol. 2018. PMID: 28737048 Review.
Cited by
- Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study.
Troschel FM, Steike DR, Roers J, Kittel C, Siats J, Parfitt R, Hesping AE, Am Zehnhoff-Dinnesen A, Neumann K, Eich HT, Scobioala S. Troschel FM, et al. Strahlenther Onkol. 2024 Oct 25. doi: 10.1007/s00066-024-02308-5. Online ahead of print. Strahlenther Onkol. 2024. PMID: 39455453 - Proton radiotherapy for solid tumors of childhood.
Cotter SE, McBride SM, Yock TI. Cotter SE, et al. Technol Cancer Res Treat. 2012 Jun;11(3):267-78. doi: 10.7785/tcrt.2012.500295. Epub 2012 Mar 15. Technol Cancer Res Treat. 2012. PMID: 22417062 Free PMC article. - [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy].
Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG. Schmidt CM, et al. HNO. 2007 Apr;55(4):299-306. doi: 10.1007/s00106-005-1368-1. HNO. 2007. PMID: 16437215 Clinical Trial. German. - Ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin followed by stem cell transplantation in patients with breast cancer.
Jillella AP, Britt GW, Litaker MS, Kallab AM, Harkness K, Garner GD. Jillella AP, et al. Med Oncol. 2000 Nov;17(4):287-92. doi: 10.1007/BF02782193. Med Oncol. 2000. PMID: 11114707 - Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
Marshall NE, Ballman KV, Michalak JC, Schomberg PJ, Burton GV, Sandler HM, Cascino TL, Jaeckle KA, Buckner JC. Marshall NE, et al. J Neurooncol. 2006 May;77(3):315-20. doi: 10.1007/s11060-005-9049-1. J Neurooncol. 2006. PMID: 16273313 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous